INCY $91.51 1.34 (1.4%)

    INCY Profile

    INCY trades on the NASDAQ.

    MEMBERSHIP
    Nasdaq 100 S&P 500
    SECTOR
    Health Care
    MARKET CAPITALIZATION

    $20 Billion

    Large-Cap
    Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

    INCY Earnings

    EPS

    0.60

    P/E

    145.02

    Q2 Earnings for Apr, May & Jun

    Tue, Jul 30, 2019

    Since Earnings Report

    INCY +14.0%

    Q3 Earnings for Jul, Aug & Sep

    Tue, Oct 29, 2019

    Since Earnings Report

    INCY +14.6%

    INCY Dividend

    Dividend Yield

    0.00%

    Dividend Rate

    $0.00

    Ex-Dividend Date

    --

    Dividend Pay Date

    --

    Dividend Frequency

    --

    Dividend Payments

    --

    INCY Charts

    52WL $57.00
    52WH $96.79
    All-Time $153.15


    INCY Industry Competitors


    BIOTECH & PHARMA
    Johnson & Johnson
    Merck
    Pfizer
    Bristol-Myers Squibb
    Amgen
    Novo Nordisk A/S
    AbbVie
    Eli Lilly
    Sanofi SA (ADR)
    Gilead Sciences



    Symbol MC DY Price Day YTD
    INCY $19.64 0.00% $91.51 -1.4% 44.0%






        TOP    




    info@symbolsurfing.com


    Symbol Surfing

    ©2019 Symbol Surfing All Rights Reserved.

    Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

    Cookies Policy Terms Of Service Privacy Policy